Skip to Content

Sibutramine Disease Interactions

There are 7 disease interactions with sibutramine:

Major

Sibutramine (Includes Sibutramine) ↔ Anorexia Nervosa

Severe Potential Hazard, High plausibility

Applies to: Anorexia Nervosa

The use of sibutramine is contraindicated in patients with anorexia nervosa. Sibutramine is an anorexiant used in the treatment of obesity.

References

  1. "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.
Major

Sibutramine (Includes Sibutramine) ↔ Cardiovascular

Severe Potential Hazard, High plausibility

Applies to: Cerebral Vascular Disorder, History - Myocardial Infarction, History - Cerebrovascular Disease, History - Thrombotic/Thromboembolic Disorder, Cardiovascular Disease

Sibutramine and its metabolites inhibit the reuptake of norepinephrine, serotonin, and dopamine and can induce substantial increases in heart rate and blood pressure in some patients. Sibutramine therapy should not be initiated in patients with uncontrolled or poorly controlled hypertension and/or a history of coronary artery disease, arrhythmias, congestive heart failure, stroke, or other severe cardiovascular or cerebrovascular disorders. All patients treated with sibutramine should have blood pressure and pulse measured prior to starting therapy and monitored at regular intervals thereafter. Sustained increases in blood pressure or pulse rate may require a dosage reduction or drug discontinuation.

References

  1. "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.
Major

Sibutramine (Includes Sibutramine) ↔ Glaucoma

Severe Potential Hazard, High plausibility

Applies to: Glaucoma (Narrow Angle)

Sibutramine and its metabolites inhibit the reuptake of norepinephrine, serotonin, and dopamine and can induce mydriasis. In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma. Therapy with sibutramine should be administered cautiously in patients with narrow-angle glaucoma or anatomically narrow angles.

References

  1. "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.
Major

Sibutramine (Includes Sibutramine) ↔ Renal/Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease, Renal Dysfunction

Sibutramine is converted by the liver to two active metabolites, which are further metabolized to inactive substances and subsequently eliminated by the kidney. Due to a lack of clinical data, the manufacturer does not recommend the use of sibutramine in patients with severe renal and/or hepatic impairment. Based on limited pharmacokinetic data, sibutramine may be administered in mild or moderate hepatic insufficiency at normally recommended dosages.

References

  1. "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.
Moderate

Obesity Drugs (Includes Sibutramine) ↔ Diabetics

Moderate Potential Hazard, High plausibility

Applies to: Diabetes Type 2

Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight. Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.

References

  1. "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.
  2. "Product Information. Xenical (orlistat)." Roche Laboratories, Nutley, NJ.
  3. "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
View all 9 references
Moderate

Sibutramine (Includes Sibutramine) ↔ Seizures

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures

Sibutramine and its metabolites inhibit the reuptake of norepinephrine, serotonin, and dopamine. In clinical trials, seizures were reported in < 0.1% of patients treated with sibutramine. Therapy with sibutramine should be administered cautiously in patients with or predisposed to seizures.

References

  1. "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.
Moderate

Sibutramine (Includes Sibutramine) ↔ Substance Abuse

Moderate Potential Hazard, Moderate plausibility

Applies to: Drug Abuse/Dependence, Alcoholism

Centrally-acting anorexiants are generally subject to habituation and abuse. While sibutramine does not appear to have a significant potential for abuse, clinical data are limited. Therapy with sibutramine should be administered cautiously in patients with a history of alcohol or substance abuse. Such patients should be observed carefully during therapy for signs of misuse of sibutramine.

References

  1. "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.

sibutramine drug Interactions

There are 983 drug interactions with sibutramine

sibutramine alcohol/food Interactions

There is 1 alcohol/food interaction with sibutramine

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide